Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.

Cancer Sci · 2022 · PMC8819353 · PMID 34808021

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

At 8 wk after treatment, either ruxolitinib or obatoclax alone, or a combination of both showed a trend, but failed to significantly reduce Hb/Ht, WBC and PLT (Figure 5B‐D ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.